Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB200 + AT2221 in Pompe disease
NCT02675465Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Apr 2016
- Primary completion
- Aug 2024
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of cipaglucosidase alfa in Pompe disease (2 arms), sponsored by Amicus Therapeutics. Primary endpoints: Treatment-emergent Adverse Events at 71 months, Maximum Observed Plasma Concentration at 18 weeks and 2 more. Started Apr 2016; status: completed.
02
Drugs
cipaglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT02675465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675465.